|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
67,990,000 |
Market
Cap: |
37.29(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.45 - $2.9 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Gritstone bio is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. Co. discovers, develops, manufactures, and delivers cancer and infectious disease immunotherapy candidates by utilizing both of its vaccine vectors, self-amplifying mRNA and chimpanzee adenovirus. Co.'s oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. Co.'s programs in clinical stage development are: CORAL, a second generation COVID-19 vaccine program and an HIV therapeutic/cure vaccine candidate that Co. is collaborating on with Gilead Sciences, Inc.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
12,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$22,829 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
74,769 |
74,769 |
74,769 |
Total Sell Value |
$0 |
$55,949 |
$55,949 |
$55,949 |
Total People Sold |
0 |
5 |
5 |
5 |
Total Sell Transactions |
0 |
5 |
5 |
5 |
End Date |
2024-06-20 |
2024-03-19 |
2023-09-19 |
2022-09-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Jones Erin |
See Remarks |
|
2019-01-29 |
4 |
OE |
$0.35 |
$3,450 |
D/D |
10,000 |
10,000 |
|
- |
|
Green Jeremy |
10% Owner |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,394,529 |
1,394,529 |
|
- |
|
Versant Affiliates Fund V, L.p. |
general partner |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,929 |
3,102,929 |
|
- |
|
Simon Nicholas |
Director |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,234,112 |
2,567,445 |
|
- |
|
Clarus Ventures Iii, Llc |
General Partner |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,234,112 |
2,567,445 |
|
- |
|
Goeddel David V |
Managing Partner |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,102,934 |
3,102,934 |
|
- |
|
Svennilson Peter |
Director |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,934 |
3,102,934 |
|
- |
|
Woiwode Thomas |
Director |
|
2018-10-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,102,929 |
3,102,929 |
|
- |
|
Simon Nicholas |
Director |
|
2018-09-28 |
4 |
B |
$15.00 |
$4,999,995 |
I/I |
333,333 |
333,333 |
2.25 |
- |
|
Clarus Ventures Iii, Llc |
General Partner |
|
2018-09-28 |
4 |
B |
$15.00 |
$4,999,995 |
D/D |
333,333 |
333,333 |
2.44 |
- |
|
85 Records found
|
|
Page 4 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|